SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Discussion centers on speculation that Middle East LNG disruptions and shipping risks could strengthen demand and pricing for U.S. exporters, including NextDecades Rio Grande project. Bulls point to the projects progress and future capacity, while skeptics emphasize that NEXT has no current LNG production or revenue and still faces construction, financing, and competition risks.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its choppy, weak trading and repeated difficulty holding above the eight-cent area, with traders also linking pressure to broader crypto-market declines. The conversation is split between bearish frustration over losses and calls to buy the dip or hold for a recovery.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Traders are focused on Zebecs payroll and payments expansion, including MoneyGram/Stellar links and Robinhood Chain support, as potential adoption drivers. Bullish holders are accumulating, while skeptics question whether actual usage will translate into ZBCN demand given its weak, uneven price performance.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic investment is drawing attention amid IPO-filing and valuation chatter, with bullish traders viewing the stake as a potential source of value. Others question whether it can offset Zooms modest core-business growth and competitive pressures; discussion also references recent earnings beats and raised full-year guidance.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths order for more than 50,000 optical assemblies for defense-drone cameras is drawing attention to its counter-drone and thermal-optics business. Bulls see room for recurring demand and further defense orders, while skeptics want earnings and revenue to confirm the growth story; broad market and defense-sector weakness have also weighed on the shares.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention for its steep, prolonged selloff and repeated tests of key support, with traders debating whether the weakness reflects valuation concerns, insider selling and a broader defense-sector pullbackor an oversold buying opportunity. Optimists point to contract wins, growth prospects and analyst upgrades, while skeptics say positive developments have not reversed the downtrend ahead of upcoming earnings.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Galaxy Digitals adoption of Skys yield-bearing stablecoin for its treasury and lending collateral, alongside a reported purchase of SKY, is driving discussion of growing institutional interest in the Sky ecosystem. Traders are watching for a breakout, while others see the recent pullback as a warning and question whether the rally can hold.

Direxion Shares ETF Trust - Direxion Daily GOOGL Bull 2X ETF

Direxion Daily GOOGL Bull 2X Shares ETF

Alphabets sharp post-earnings selloff is driving attention to GGLL, with many traders buying the dip for a rebound while others warn that market weakness and deteriorating technicals could bring further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor...

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger   

Equity

Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.


Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor...

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at the International Association for the Study of Lung Cancer's...

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the...

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500...

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE

The Biology Came First.

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...

Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The shares were...

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Safety questions around zipalertinib from mid-September late-stage lung cancer results added to the pressure on the stock.&nbsp;</li><li>In December, the company plans to report both multi-dose and single-target-dose results for CLN-978, across treatment-refractory SLE, difficult-to-treat RA, and treatment-refractory Sjögren’s disease.</li><li>TD Cowen argued the recent weakness offers a chance to buy before those updates.</li></ul> Cullinan Therapeutics (CGEM) shares tumbled as much as 12% on Thursday after the company outlined fourth-quarter pipeline updates that pushed rheumatoid arthritis data later than previously signaled.The decline reflected a broader sell-off in clinical-stage biotech names and investor disappointment that additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December along with results in lupus and Sjögren’s disease.Safety questions around zipalertinib from mid-September late-stage lung cancer results added to the pressure. Grade 3 or higher adverse events were substantially higher with the combination than chemotherapy alone.At the time of writing, the stock was down 5%, after a 22% drop on Wednesday. &nbsp;<h2 class="st-heading-2">Q4 Data Calendar</h2>Cullinan said it will present multi-dose regimen data for velinotamig from an ongoing early-stage study in systemic lupus erythematosus (SLE) at the American College of Rheumatology meeting on Nov. 8.In December, the company plans to report both multi-dose and single-target-dose results for CLN-978, across treatment-refractory SLE, difficult-to-treat RA, and treatment-refractory Sjögren’s disease. Chief Executive Nadim Ahmed described the package as the most comprehensive clinical dataset to date for a drug in the category spanning those indications.The same month, Cullinan intends to share longer follow-up from the dose-escalation portion of its early-stage study of CLN-049 in relapsed or refractory acute myeloid leukemia. After a recent successful FDA meeting, the company said it is moving toward a potentially registrational mid-stage trial.<h2 class="st-heading-2">Analyst Says Buy</h2>TD Cowen, which rates the stock Buy, said the fourth-quarter slate is full of events that could help set mid-stage plans for CLN-978 in lupus, RA, and Sjögren’s and test how durable CLN-049 looks in relapsed or refractory AML. The firm argued the recent weakness offers a chance to buy before those updates.<h2 class="st-heading-2">How Did CGEM Retail Traders React?</h2>On Stocktwits, retail sentiment around CGEM stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user said the selloff doesn’t match the news.<stembedurl>https://stocktwits.com/ImFullyTorqued/message/665015963</stembedurl><a href="https://stocktwits.com/symbol/CGEM">CGEM stock</a> has gained 55% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kytx-stock-reverses-gains-after-one-year-cell-therapy-trial-data-but-ceo-says-disease-burden-justifies-a-premium-price/cZMJ9W5RB9t">KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Cullinan Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger

Cullinan Oncology Inc

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$CGEM - CD19 selloff appears over, now look toward BCMA data at ACR meeting Nov 8th for the catalyst players out there

Jonathan Faison

Latest company news, October 19, 2026: Cullinan and Taiho reported zipalertinib intracranial ORR of 30.2% (43 evaluable patients, EGFR exon 20 NSCLC with active CNS metastases); ESMO poster on October 26. 
 
Cullinan Therapeutics ($CGEM): First-Line Zipalertinib NDA 
Deeper dive in our hub. 
Not investment advice.

Merlintrader Trading Pub

$CGEM H.C. Wainwright reiterated a Buy rating and $35 price target on Cullinan Oncology Inc. (NASDAQ:CGEM) following the company’s announcement of a rolling NDA submission for zipalertinib.

Anton Chekhov

$CGEM — Velinotamig: FDA and Australia cleared Phase 1b/2a in ITP and wAIHA. 
 
Information only — not investment advice. 
 
More details in our hub.

$CGEM 🏥 

Cullinan Therapeutics received U.S. FDA and Australian TGA clearance to initiate a Phase 1b/2a study of Velinotamig in relapsing/refractory ITP and warm autoimmune hemolytic anemia.

Rayvio | Market News Filter

$CGEM I see a lot of upside potential in this one over the next 6-8 weeks. Greatly undervalued with potentiallly major catalysts incoming between now and end of 2026. Institutions will start adding and volume will increase. Very

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGEM Cullinan Oncology Inc

Fundamentals

Latest CGEM News